Overview

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Status:
Completed
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Apatinib